SCHEMBL6038452

SCHEMBL6038452

CCCc1ccc(S(=O)(=O)Nc2nccnc2OCCOc2ccccc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.46
KMT2A Q03164 6/20 0.46
CCR2 P41597 1/20 0.45
HTT P42858 4/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
TSHR P16473 1/20 0.45
CYP2C19 P33261 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
LMNA P02545 3/20 0.44
ALDH1A1 P00352 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MAPT P10636 2/20 0.43
FFAR4 Q5NUL3 1/20 0.43
NR1I2 O75469 1/20 0.42
KDM4E B2RXH2 1/20 0.42
HSD17B10 Q99714 1/20 0.42
ALOX12 P18054 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038515 0.91 KMT2A (0.49) MEN1KMT2ACCR2HTTCYP1A2
SCHEMBL6038954 0.86 KMT2A (0.50) MEN1KMT2ACCR2HTTSMN1; SMN2
SCHEMBL6038497 0.85 KMT2A (0.64) MEN1KMT2AHTTLMNAALDH1A1
SCHEMBL6038505 0.84 PTGDR2 (0.50) MEN1KMT2ACCR2HTTLMNA
SCHEMBL6038562 0.84 KMT2A (0.49) MEN1KMT2ACCR2HTTLMNA
SCHEMBL6038416 0.84 TSHR (0.51) MEN1KMT2ACCR2TSHRLMNA
SCHEMBL6039220 0.84 MEN1 (0.53) MEN1KMT2ACCR2ALDH1A1FFAR4
SCHEMBL6039126 0.84 AR (0.50) MEN1KMT2ACCR2HTTSMN1; SMN2
SCHEMBL6038581 0.83 MEN1 (0.50) MEN1KMT2ACCR2HTTCYP1A2
SCHEMBL6039027 0.82 MEN1 (0.44) MEN1KMT2ACCR2HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 MEN1 2431/4885KMT2A 4190/4885CCR2 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.